0000950170-24-049928.txt : 20240429 0000950170-24-049928.hdr.sgml : 20240429 20240429163023 ACCESSION NUMBER: 0000950170-24-049928 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20240429 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240429 DATE AS OF CHANGE: 20240429 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Iterum Therapeutics plc CENTRAL INDEX KEY: 0001659323 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38503 FILM NUMBER: 24891444 BUSINESS ADDRESS: STREET 1: FITZWILLIAM COURT, 1ST FLOOR STREET 2: LEESON CLOSE CITY: DUBLIN 2 STATE: L2 ZIP: D02 YW24 BUSINESS PHONE: (872) 225-6077 MAIL ADDRESS: STREET 1: FITZWILLIAM COURT, 1ST FLOOR STREET 2: LEESON CLOSE CITY: DUBLIN 2 STATE: L2 ZIP: D02 YW24 FORMER COMPANY: FORMER CONFORMED NAME: Iterum Therapeutics Ltd DATE OF NAME CHANGE: 20151124 8-K 1 itrm-20240429.htm 8-K 8-K
0001659323false00-000000000016593232024-04-292024-04-29

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 29, 2024

 

 

Iterum Therapeutics plc

(Exact name of Registrant as Specified in Its Charter)

 

 

Ireland

001-38503

Not applicable

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

Fitzwilliam Court

1st Floor

Leeson Close

 

Dublin 2, , Ireland

 

Not applicable

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: +353 1 6694820

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Ordinary Shares, par value $0.01 per share

 

ITRM

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 8.01 Other Events.

On April 29, 2024, Iterum Therapeutics plc issued a press release announcing that it had resubmitted its New Drug Application to the U.S. Food and Drug Administration for sulopenem etzadroxil/probenecid (oral sulopenem) for the treatment of uncomplicated urinary tract infections in adult women.

 

The full text of the press release issued in connection with this announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

 

 

Exhibit No.

Description

99.1

Press Release of Iterum Therapeutics plc dated April 29, 2024

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Iterum Therapeutics plc

 

 

 

 

Date:

April 29, 2024

By:

/s/ Corey N. Fishman

 

 

 

Corey N. Fishman
Chief Executive Officer

 

 EX-99.1 2 itrm-ex99_1.htm EX-99.1 EX-99.1

 

Exhibit 99.1

Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem

 

--First Oral Penem in the U.S. and Second New Oral Treatment for uUTIs in Over 25 Years, if approved--

 

--Potential Approval Early Q4 2024--

 

 

DUBLIN, Ireland and CHICAGO, April 29, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for sulopenem etzadroxil/probenecid (oral sulopenem) for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women.

“The resubmission of the NDA filing for oral sulopenem is a significant step forward in bringing a new antibiotic to the market for women that suffer from an estimated 40 million uUTIs each year in the U.S.,” said Corey Fishman, Chief Executive Officer. “The availability of oral sulopenem, if approved, would mean that physicians and patients have the opportunity to benefit from the proven efficacy and safety of penem antibiotics that, to date in the U.S., have only been available in IV formulations. We look forward to working with the FDA through the review process to advance this much needed treatment option."

The NDA resubmission includes data from the REASSURE (REnewed ASsessment of Sulopenem in uUTI caused by Resistant Enterobacterales), SURE (Sulopenem for Resistant Enterobacteriaceae) 1, SURE 2 and SURE 3 phase 3 clinical trials, in which oral sulopenem was well tolerated with no safety issues identified. The REASSURE clinical trial comparing oral sulopenem to oral Augmentin® in adult women with a uUTI, demonstrated that oral sulopenem was non-inferior to Augmentin® for the primary efficacy endpoint of clinical and microbiologic response at the test-of-cure visit for patients with an Augmentin® susceptible pathogen, with the difference in the overall success rate demonstrating statistically significant superiority of oral sulopenem versus Augmentin®. The SURE 1 clinical trial comparing oral sulopenem to oral ciprofloxacin in adult women with a uUTI, demonstrated statistical superiority of oral sulopenem to the widely used comparator, ciprofloxacin, for the primary efficacy endpoint of clinical and microbiologic response at the test-of-cure visit for patients with a quinolone non-susceptible pathogen.

Provided that the resubmitted NDA addresses all of the deficiencies identified in the complete response letter (CRL) the Company received from the FDA in July 2021, the Company expects that the FDA will complete its review and take action six months from the date the FDA received the resubmitted NDA (or early in the fourth quarter of 2024).

About Iterum Therapeutics plc

Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. The Company is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. The Company has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications.

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the Company’s plans, strategies and prospects for its business, including the development, therapeutic and market potential of sulopenem, the Company’s ability to address the deficiencies set out in the CRL received in July 2021, and the expected timing of review of the NDA by the FDA. In some cases, forward-looking statements can be identified by words such as “may,” “believes,” “intends,” “seeks,” “anticipates,” “plans,” “estimates,” “expects,” “should,” “assumes,” “continues,” “could,” “would,” “will,” “future,” “potential” or the negative of these or similar terms and phrases. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include all matters that are not historical facts. Actual future results may be materially different from what is expected due to factors largely outside the Company’s control, including the uncertainties inherent in the initiation and conduct of clinical and non-clinical development, changes in regulatory requirements or decisions of regulatory authorities, the timing of approval of any submission, changes in public policy or legislation, commercialization plans and timelines, if oral sulopenem is approved, the actions of third-party clinical research organizations, suppliers and manufacturers, the accuracy of the Company’s expectations regarding how far into the future the Company’s cash on hand will fund the Company’s ongoing operations, the sufficiency of the Company’s cash resources and the Company’s ability to continue as a going concern, the Company’s ability to maintain listing on the Nasdaq Capital Market, risks and uncertainties concerning the outcome, impact, effects and results of the Company’s pursuit of strategic alternatives, including the terms, timing, structure, value, benefits and costs of any strategic process and the Company’s ability to complete one, whether on attractive terms or at all, and other factors discussed under the caption “Risk Factors” in its most recently filed Annual Report on Form 10-K filed with the US Securities and Exchange Commission (SEC) on March 28, 2024, and other documents filed with the SEC from time to time. Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this press release. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Investor Contact:

Judy Matthews

Chief Financial Officer 312-778-6073

IR@iterumtx.com

 

 EX-101.SCH 3 itrm-20240429.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, Country Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 5 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Document And Entity Information
Apr. 29, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 29, 2024
Entity Registrant Name Iterum Therapeutics plc
Entity Central Index Key 0001659323
Entity Emerging Growth Company false
Entity File Number 001-38503
Entity Incorporation, State or Country Code L2
Entity Tax Identification Number 00-0000000
Entity Address, Address Line One Fitzwilliam Court
Entity Address, Address Line Two 1st Floor
Entity Address, Address Line Three Leeson Close
Entity Address, City or Town Dublin 2
Entity Address, Country IE
Entity Address, Postal Zip Code Not applicable
City Area Code +353
Local Phone Number 1 6694820
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Ordinary Shares, par value $0.01 per share
Trading Symbol ITRM
Security Exchange Name NASDAQ
EXCEL 6 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

#G5@ZJJ+G0 $ #P" / " 8D0 !X M;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " #'@YU8)!Z;HJT #X 0 &@ M @ 'V$0 >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$" M% ,4 " #'@YU899!YDAD! #/ P $P @ ';$@ 6T-O F;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" E% ! end XML 7 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 8 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.iterumtx.com/20240429/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports itrm-20240429.htm itrm-20240429.xsd http://xbrl.sec.gov/dei/2023 false false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "itrm-20240429.htm": { "nsprefix": "itrm", "nsuri": "http://www.iterumtx.com/20240429", "dts": { "inline": { "local": [ "itrm-20240429.htm" ] }, "schema": { "local": [ "itrm-20240429.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 26, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://www.iterumtx.com/20240429/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_77f74ad0-bc28-4fbc-b68c-ec09cbf355af", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "itrm-20240429.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_77f74ad0-bc28-4fbc-b68c-ec09cbf355af", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "itrm-20240429.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.iterumtx.com/20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.iterumtx.com/20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.iterumtx.com/20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.iterumtx.com/20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.iterumtx.com/20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.iterumtx.com/20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://www.iterumtx.com/20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.iterumtx.com/20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://www.iterumtx.com/20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.iterumtx.com/20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.iterumtx.com/20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.iterumtx.com/20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.iterumtx.com/20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.iterumtx.com/20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.iterumtx.com/20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.iterumtx.com/20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.iterumtx.com/20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.iterumtx.com/20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.iterumtx.com/20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.iterumtx.com/20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.iterumtx.com/20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.iterumtx.com/20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.iterumtx.com/20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.iterumtx.com/20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.iterumtx.com/20240429/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 13 0000950170-24-049928-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-049928-xbrl.zip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end XML 15 itrm-20240429_htm.xml IDEA: XBRL DOCUMENT 0001659323 2024-04-29 2024-04-29 0001659323 false 00-0000000 8-K 2024-04-29 Iterum Therapeutics plc L2 001-38503 Fitzwilliam Court 1st Floor Leeson Close Dublin 2 IE Not applicable +353 1 6694820 false false false false Ordinary Shares, par value $0.01 per share ITRM NASDAQ false